Timing of Antimicrobial Prophylaxis and Tourniquet Inflation: A Randomized Controlled Microdialysis Study.
Animals
Female
Adipose Tissue
/ chemistry
Anti-Bacterial Agents
/ administration & dosage
Antibiotic Prophylaxis
/ methods
Cancellous Bone
/ chemistry
Cefuroxime
/ administration & dosage
Hindlimb
/ surgery
Injections, Intravenous
Microbial Sensitivity Tests
Microdialysis
/ methods
Swine
Time Factors
Tourniquets
Journal
The Journal of bone and joint surgery. American volume
ISSN: 1535-1386
Titre abrégé: J Bone Joint Surg Am
Pays: United States
ID NLM: 0014030
Informations de publication
Date de publication:
04 Nov 2020
04 Nov 2020
Historique:
pubmed:
10
8
2020
medline:
21
4
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios. Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified. Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone. Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release. Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
Sections du résumé
BACKGROUND
BACKGROUND
Tourniquets are widely used during extremity surgery. In order to prevent surgical site infection, correct timing of antimicrobial prophylaxis and tourniquet inflation is important. We aimed to evaluate the time for which the free drug concentration of cefuroxime is maintained above the minimum inhibitory concentration (t > MIC) in porcine subcutaneous adipose tissue and calcaneal cancellous bone during 3 clinically relevant tourniquet application scenarios.
METHODS
METHODS
Twenty-four female Danish Landrace pigs were included. Microdialysis catheters were placed bilaterally for sampling of cefuroxime concentrations in calcaneal cancellous bone and subcutaneous adipose tissue, and a tourniquet was applied to a randomly picked leg of each pig. Subsequently, the pigs were randomized into 3 groups to receive 1.5 g of cefuroxime by intravenous injection 15 minutes prior to tourniquet inflation (Group A), 45 minutes prior to tourniquet inflation (Group B), and at the time of tourniquet release (Group C). The tourniquet duration was 90 minutes in all groups. Dialysates and venous blood samples were collected for 8 hours after cefuroxime administration. Cefuroxime and various ischemic marker concentrations were quantified.
RESULTS
RESULTS
Cefuroxime concentrations were maintained above the clinical breakpoint MIC for Staphylococcus aureus (4 µg/mL) in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet duration in Groups A and B. Cefuroxime administration at the time of tourniquet release (Group C) resulted in concentrations of >4 µg/mL for approximately of 3.5 hours in the tissues on the tourniquet side. Furthermore, tourniquet application induced ischemia (increased lactate:pyruvate ratio) and cell damage (increased glycerol) in subcutaneous adipose tissue and calcaneal cancellous bone. Tissue ischemia was sustained for 2.5 hours after tourniquet release in calcaneal cancellous bone.
CONCLUSIONS
CONCLUSIONS
Administration of cefuroxime (1.5 g) in the 15 to 45-minute window prior to tourniquet inflation resulted in sufficient concentrations in calcaneal cancellous bone and subcutaneous adipose tissue throughout the 90-minute tourniquet application. Furthermore, tourniquet-induced tissue ischemia fully resolved 2.5 hours after tourniquet release.
CLINICAL RELEVANCE
CONCLUSIONS
Cefuroxime administration 15 to 45 minutes prior to tourniquet inflation seems to be a safe window. If the goal is to maintain postoperative cefuroxime concentrations above relevant MIC values, our results suggest that a second dose of cefuroxime should be administered at the time of tourniquet release.
Identifiants
pubmed: 32769808
doi: 10.2106/JBJS.20.00076
pii: 00004623-202011040-00004
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cefuroxime
O1R9FJ93ED
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1857-1864Références
Rama KR, Apsingi S, Poovali S, Jetti A. Timing of tourniquet release in knee arthroplasty. Meta-analysis of randomized, controlled trials. J Bone Joint Surg Am. 2007 Apr;89(4):699-705. Epub 2007 Apr 04.
Smith TO, Hing CB. Is a tourniquet beneficial in total knee replacement surgery? A meta-analysis and systematic review. Knee. 2010 Mar;17(2):141-7. Epub 2009 Jul 19.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.
Ochsner PE, Borens O, Bodler PM, Broger I, Eich G, Hefti F, Maurer T, Nötzli H, Seiler S, Suvà D, Trampuz A, Uçkay I, Vogt M, Zimmerli W. Infections of the musculoskeletal system: basic principles, prevention, diagnosis and treatment. Grandvaux: Swiss orthopaedics in-house publisher; 2016.
Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008 May;16(5):283-93.
Johnson DP. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Joint Surg Br. 1987 Nov;69(5):787-9.
Deacon JS, Wertheimer SJ, Washington JA. Antibiotic prophylaxis and tourniquet application in podiatric surgery. J Foot Ankle Surg. 1996 Jul-Aug;35(4):344-9.
Soriano A, Bori G, García-Ramiro S, Martinez-Pastor JC, Miana T, Codina C, Maculé F, Basora M, Martínez JA, Riba J, Suso S, Mensa J. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis. 2008 Apr 1;46(7):1009-14.
Ejaz A, Laursen AC, Kappel A, Jakobsen T, Nielsen PT, Rasmussen S. Tourniquet induced ischemia and changes in metabolism during TKA: a randomized study using microdialysis. BMC Musculoskelet Disord. 2015 Oct 29;16:326.
Ostman B, Michaelsson K, Rahme H, Hillered L. Tourniquet-induced ischemia and reperfusion in human skeletal muscle. Clin Orthop Relat Res. 2004 Jan;418:260-5.
Kho CM, Enche Ab Rahim SK, Ahmad ZA, Abdullah NS. A review on microdialysis calibration methods: the theory and current related efforts. Mol Neurobiol. 2017 Jul;54(5):3506-27. Epub 2016 May 17.
Bue M, Thomassen MB, Larsen OH, Jørgensen AR, Stilling M, Søballe K, Hanberg P. Local vancomycin concentrations after intra-articular injection into the knee joint: an experimental porcine study. J Knee Surg. 2019 Dec 30. Epub 2019 Dec 30.
Tøttrup M, Søballe K, Bibby BM, Hardlei TF, Hansen P, Fuursted K, Birke-Sørensen H, Bue M. Bone, subcutaneous tissue and plasma pharmacokinetics of cefuroxime in total knee replacement patients - a randomized controlled trial comparing continuous and short-term infusion. APMIS. 2019 Dec;127(12):779-88. Epub 2019 Oct 14.
Hanberg P, Bue M, Öbrink-Hansen K, Kabel J, Thomassen M, Tøttrup M, Søballe K, Stilling M. Simultaneous retrodialysis by drug for cefuroxime using meropenem as an internal standard-a microdialysis validation study. J Pharm Sci. 2020 Mar;109(3):1373-9. Epub 2019 Nov 20.
Chaurasia CS, Müller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007 May;24(5):1014-25. Epub 2007 Mar 27.
Joukhadar C, Müller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet. 2005;44(9):895-913.
Hanberg P, Öbrink-Hansen K, Thorsted A, Bue M, Tøttrup M, Friberg LE, Hardlei TF, Søballe K, Gjedsted J. Population pharmacokinetics of meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02390-17.
Korth U, Merkel G, Fernandez FF, Jandewerth O, Dogan G, Koch T, van Ackern K, Weichel O, Klein J. Tourniquet-induced changes of energy metabolism in human skeletal muscle monitored by microdialysis. Anesthesiology. 2000 Dec;93(6):1407-12.
European Society of Clinical Microbiology and Infectious Diseases. Antimicrobial wild type distributions of microorganisms. Accessed 2020 Jun 29. https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=46&Specium=-12019
Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992 Jan 30;326(5):281-6.
Schutzer SF, Harris WH. Deep-wound infection after total hip replacement under contemporary aseptic conditions. J Bone Joint Surg Am. 1988 Jun;70(5):724-7.
van Kasteren ME, Manniën J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis. 2007 Apr 1;44(7):921-7. Epub 2007 Feb 14.
Hawn MT, Richman JS, Vick CC, Deierhoi RJ, Graham LA, Henderson WG, Itani KM. Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg. 2013 Jul;148(7):649-57.
Zelenitsky SA, Ariano RE, Harding GK, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agents Chemother. 2002 Sep;46(9):3026-30.
Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sörgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89-124.
Bue M, Hanberg P, Tøttrup M, Thomassen MB, Birke-Sørensen H, Thillemann TM, Andersson TL, Søballe K. Vancomycin concentrations in the cervical spine after intravenous administration: results from an experimental pig study. Acta Orthop. 2018 Dec;89(6):683-8. Epub 2018 Aug 6.
Bue M, Tøttrup M, Hanberg P, Langhoff O, Birke-Sørensen H, Thillemann TM, Andersson TL, Søballe K. Bone and subcutaneous adipose tissue pharmacokinetics of vancomycin in total knee replacement patients. Acta Orthop. 2018 Feb;89(1):95-100. Epub 2017 Sep 15.
Hanberg P, Bue M, Birke Sørensen H, Søballe K, Tøttrup M. Pharmacokinetics of single-dose cefuroxime in porcine intervertebral disc and vertebral cancellous bone determined by microdialysis. Spine J. 2016 Mar;16(3):432-8. Epub 2015 Nov 24.
Hanberg P, Lund A, Søballe K, Bue M. Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: an animal study. Bone Joint Res. 2019 Aug 2;8(7):313-22.
Swindle MM, Makin A, Herron AJ, Clubb FJ Jr, Frazier KS. Swine as models in biomedical research and toxicology testing. Vet Pathol. 2012 Mar;49(2):344-56. Epub 2011 Mar 25.